FLT3 and acute myeloid leukemia: This information is over great clinical value in the area of Nivolumab (anti-PD-1 (CD279) monoclonal antibody) therapy opening a new avenue for treatment of AML patients having over dismal prognosis FLT3 ITD mutation and relapsing post HSCT [17].